IFNAR
Interferon-α/β receptor; Interferon-alpha/beta receptor
The interferon-α/β receptor (IFNAR) is composed of two subunits, IFNAR1 and IFNAR2, encoding transmembrane polypeptides. Type-I IFNs, interferon α (IFN-α) and interferon β (IFN-β), act through a shared receptor complex, IFNAR. Binding of type-I IFN to IFNAR1 will robustly activate Janus activated kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway. Aberrant activation of the type-I IFN response results in a spectrum of disorders called interferonopathies.
Type-I IFN response occurs when IFN-α/β binds to their receptor complex, IFNAR. The ligand-receptor complex is phosphorylated, presumably by pre-associated Janus activated kinases (JAKs) namely tyrosine kinase 2 (TYK2) on IFNAR1 and JAK1 on IFNAR2. The phosphorylated receptors are docking sites for signal transducers and activators of transcription (STAT) factors that dimerise and translocate to the nucleus. STATs 1, 2, 3, 4, and 5 are activated by type-I IFNs in many cell types. Other kinases (e.g., mitogen-activated protein kinases) and transcription factors (e.g., nuclear factor-κB) can also be activated in response to type-I IFNs. Multiple pathways and IFN-regulated genes are activated by IFNs, many of which remain unknown.
All Product Categories
-
IFNAR Inhibitors
(129)
View all products
-
IFNAR Agonists
(11)
View all products
-
IFNAR Antagonists
(6)
View all products
-
IFNAR Activators
(85)
View all products
-
IFNAR Modulators
(4)
View all products
-
IFNAR Inducers
(23)
View all products
-
IFNAR Degrader
(1)
View all products
-
IFNAR Control
(1)
View all products
-
IFNAR Ligand
(1)
View all products
-
IFN-α/β Receptor Proteins
(16)
View all products
-
IFN-alpha/beta R2 Proteins
(6)
View all products
-
IFNAR Related Products (334)
Related Products (334)
-
Recombinant Proteins (16)
-
Antibodies (14)
-
Omtriptolide sodium
0 ImagesCat. No.: HY-16362CAS No.: 195883-09-1Synonyms: PG 490-88NaOmtriptolide sodium (PG490-88Na) is a derivative of Triptolide (HY-32735). Omtriptolide sodium exhibits significant immunosuppressive, anti-fibrotic and anti-inflammatory properties. The mechanism of action of Omtriptolide sodium is diverse, including inhibiting T cell activation and proliferation, inducing T cell apoptosis (apoptosis), blocking fibroblast maturation/proliferation, inhibiting TGF-β mRNA expression, and suppressing pro-inflammatory cytokines (such as IL-2, IFN-γ, TNF-α) by blocking transcription factors such as NF-κB. Omtriptolide sodium can be used for research on obstructive airway diseases, pulmonary fibrosis and graft-versus-host disease.
-
MSP-1 (20-39)
0 ImagesCat. No.: HY-P11123CAS No.: 158470-47-4MSP-1 (20-39) is a peptide segment that can induce the production of IFN-γ. MSP-1 (20-39) has the potential to serve as a malaria vaccine. MSP-1 (20-39) can be used for research on malaria or immunology.
-
MOG 37-46
0 ImagesCat. No.: HY-P11796CAS No.: 1235835-17-2MOG 37-46 is a dominant immunodominant CD8+ T cell epitope. As a truncated version of MOG35-55, MOG 37-46 is recognizable by MOG 35-55-specific T cells, and serves as an autoantibody target at the dimer interface of the extracellular domain of myelin oligodendrocyte glycoprotein (MOG). MOG 37-46 stimulates MOG-specific CD8+ T cell lines and proinflammatory CD8+ T cells migrating into the central nervous system (CNS) to produce IFN-γ. MOG 37-46 is applicable to research related to experimental autoimmune encephalomyelitis.
-
MG-1131
0 ImagesCat. No.: HY-P991475MG-1131 is a human monoclonal antibody (mAb) targeting TIGIT. MG-1131 activates NF-κB signaling in T cells and enhances NK-mediated tumor killing activity in a PVR-dependent manner. MG-1131 blocks TIGIT to increase IFN-γ secretion. MG-1131 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
-
SF-9-2
0 ImagesCat. No.: HY-175236CAS No.: 3053768-78-5SF-9-2 is a PD-L1/PD-1 binding inhibitor (IC50 = 24.9 nM). SF-9-2 inhibits epithelial-mesenchymal transition, migration, invasion, and proliferation of SK-N-SH cells, and also induces apoptosis and cell cycle arrest. SF-9-2 blocks PD-L1-induced SK-N-SH cell growth through the MAPK signaling pathway. SF-9-2 restores GSK-3β activity and enhances PD-L1 degradation through the ubiquitin-proteasome pathway. SF-9-2 inhibits tumor growth in the SK-N-SH NOG mouse model without significant toxicity. SF-9-2 also acts as an immune checkpoint inhibitor, blocking PD-L1 to restore T cell function. SF-9-2 can be used in neuroblastoma research.
-
PO-322
0 ImagesCat. No.: HY-187958CAS No.: 91837-56-8PO-322 is a selective SGK1 inhibitor with an IC50 of 54 nM. PO-322 reduces NDRG1 phosphorylation through inhibition of SGK1. PO-322 inhibits T cell proliferation and the production of IL-17, IFN-γ, and IL-6, accompanied by upregulated phosphorylation of p70S6K and STAT5. PO-322 exhibits immunosuppressive activity both in vitro and in vivo, and attenuates DNFB-induced delayed-type hypersensitivity and Imiquimod (HY-B0180)-induced psoriasis-like dermatitis. PO-322 is useful for research related to autoimmune diseases and psoriasis.
-
PD-L1-IN-12
0 ImagesCat. No.: HY-184989PD-L1-IN-12 is an orally active and potent selenium-containing small-molecule PD-L1 inhibitor (KD = 9.06 nM). PD-L1-IN-12 can mediate the internalization of PD-L1 and strongly block hPD-1 and hPD-L1 interaction (IC50 = 5.2 nM). PD-L1-IN-12 can be used in colorectal cancer immunology research.
-
S-570
0 ImagesCat. No.: HY-189280CAS No.: 2718206-92-7
-
Eps8 peptide 327
0 ImagesCat. No.: HY-P10994CAS No.: 1988684-26-9Synonyms: Eps8(327-335)Eps8 peptide 327 is an HLA-A*2402-restricted peptide antigen derived from Eps8 protein. Eps8 peptide 327 has potent antitumor activity with significant cytotoxicity. Eps8 peptide 327 effectively inhibits cancer cells proliferation, induces apoptosis and disrupts EGFR signal pathway by inhibiting downstream signals (such as IL-2, TNF-α and IFN-γ) expression and the Eps8/EGFR interaction. Eps8 peptide 327 significantly inhibits tumor growth in HT-29 xenograft mcie models.
-
PTD-N5-1 acetate
0 ImagesCat. No.: HY-P11003APurity: 99.30%PTD-N5-1 acetate is an IRF5 inhibitory peptide. PTD-N5-1 acetate blocks the activation of IRF5. PTD-N5-1 acetate inhibits β-glucan-induced IL-12 production in bone marrow-derived dendritic cells pre-stimulated with IFN-γ. PTD-N5-1 acetate reduces the levels of IL-12 and IFN-γ in the kidneys of mice with Candida albicans infection. PTD-N5-1 acetate is applicable to the research of Candida albicans infection.
-
diABZI-i
0 ImagesCat. No.: HY-175167diABZI-i is an orthogonal STING inhibitor. diABZI-i significantly inhibits cGAMP-induced IFNβ in PBMCs. diABZI-i also activates constitutive signaling of V155M SAVI and exerts potent agonistic effects in the STING V155M THP-1 cell model. diABZI-i can be used for research on monogenic autoinflammatory diseases such as SAVI.
-
FITC-labeled ODN 1585 sodium
0 ImagesCat. No.: HY-150725BFITC-labeled ODN 1585 (sodium) is a potent inducer of IFN and TNFα production. FITC-labeled ODN 1585 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.
-
PROTAC STING Degrader-2
0 ImagesCat. No.: HY-158036CAS No.: 3023095-61-3PROTAC STING Degrader-2 is a STING PROTAC degrader with a DC50 of 0.53 μM. PROTAC STING Degrader-2 reduces the phosphorylation levels of TBK1 and IRF3. PROTAC STING Degrader-2 decreases the mRNA expression levels of IFN-β, CXCL10 and TNF-α, and blocks luciferase secretion. PROTAC STING Degrader-2 can be used in the research of autoimmune diseases.
-
Anti-Mouse IFN Alpha Antibody (TIF-3C5)
0 ImagesCat. No.: HY-P991811Anti-Mouse IFN Alpha Antibody (TIF-3C5) reacts with the mouse IFNα. Anti-Mouse IFN Alpha Antibody (TIF-3C5) binds specifically to mouse IFNα species (IFN-α-A, IFN-α-1, IFN-α-4, IFN-α-5, IFN-α-11. and IFN-α-13) and does not bind murine murine IFNγ or IFNβ. Recommend Isotype Controls: Polyclonal Armenian hamster IgG, Isotype Control (HY-P990305).
-
nNOS-IN-2 trihydrochloride
0 ImagesCat. No.: HY-181545ACAS No.: 3124168-27-7nNOS-IN-2 trihydrochloride is a blood-brain barrier-permeable nitric oxide synthase (nNOS) inhibitor. nNOS-IN-2 trihydrochloride exhibits Ki values of 1.7 nM and 2.3 nM against human and rat nNOS, respectively, and shows high selectivity for human eNOS and iNOS. nNOS-IN-2 trihydrochloride also effectively reduces PD-L1 expression in human melanoma cells under both basal conditions and IFN-γ exposure. nNOS-IN-2 trihydrochloride can be used for the study of melanoma and related signaling pathways.
-
STING agonist-50
0 ImagesCat. No.: HY-181484CAS No.: 3058842-90-0STING agonist-50 is an orally active STING agonist with an IC50 of 3.457 μM. STING agonist-50 activates the STING signaling pathway and promotes the phosphorylation of downstream TBK1 and IRF3. STING agonist-50 induces the expression of IFN-β, CXCL10 and IL-6. STING agonist-50 inhibits tumor growth in syngeneic mouse models. STING agonist-50 can be used for the research of colorectal cancer.
-
GSK2245035 maleate
0 ImagesCat. No.: HY-118250ACAS No.: 1325212-97-2GSK2245035 maleate is a highly potent and selective intranasal Toll-Like receptor 7 (TLR7) agonist with preferential Type-1 interferon (IFN)-stimulating properties. GSK2245035 maleate has pEC50s of 9.3 and 6.5 for IFNα and TFNα. GSK2245035 maleate effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood cell cultures. GSK2245035 maleate is used for asthma.
